Vaxcyte, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PCVX research report →
About the company
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases.
- CEO
- Grant E. Pickering
- IPO
- 2020
- Employees
- 507
- HQ
- San Carlos, CA, US
Price Chart
Get TickerSpark's AI analysis on PCVX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $8.12B
- P/E
- -8.16
- P/S
- 0.00
- P/B
- 2.62
- EV/EBITDA
- -8.66
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.51%
- ROIC
- -34.98%
- Revenue
- $0 · 0.00%
- Net Income
- $-766,628,000 · -65.25%
- EPS
- $-5.63 · -48.16%
- Op Income
- $-923,675,000
- FCF YoY
- -40.89%
- 52W High
- $65.00
- 52W Low
- $29.08
- 50D MA
- $52.42
- 200D MA
- $51.34
- Beta
- 1.22
- Avg Volume
- 1.60M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 16, 26 | Markels John | other | 23,029 |
| Jul 16, 26 | Markels John | other | 0 |
| Jul 6, 26 | GUGGENHIME ANDREW | other | 10,000 |
| Jul 6, 26 | GUGGENHIME ANDREW | other | 10,000 |
| Jul 6, 26 | GUGGENHIME ANDREW | sell | 7,913 |
| Jul 6, 26 | GUGGENHIME ANDREW | sell | 2,087 |
| Jul 1, 26 | Wassil Jim | other | 516 |
| Jul 1, 26 | Wassil Jim | sell | 1,788 |
| Jul 1, 26 | Wassil Jim | sell | 456 |
| Jul 1, 26 | Wassil Jim | sell | 6 |
Our PCVX coverage
Recent articles, reports, and earnings notes.
What to Watch as Alopexx, Inc. Prices Its NASDAQ IPO
Alopexx, Inc. (ALPX) is expected to list on NASDAQ on 2026-07-07, but the company has not disclosed a price range or share count yet. The setup is a binary biotech story: broad anti-infective science with a small cash base, but a long path to pivotal data and more capital.
Vesicor Therapeutics Is Going Public via SPAC — Here’s the Setup
Vesicor Therapeutics, a preclinical oncology gene-therapy company, is going public via merger with Black Hawk Acquisition Corp (BKHA). The deal is still pending in the latest June 2026 filing, and the setup hinges on whether redemptions and dilution leave enough capital for a real biotech runway.
Want a deeper read on PCVX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.